XORTX Therapeutics (XORTX Therapeutics) 3-Year EBITDA Growth Rate : -87.20% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics 3-Year EBITDA Growth Rate?

XORTX Therapeutics's EBITDA per Share for the three months ended in Sep. 2023 was $-0.69.

During the past 3 years, the average EBITDA Per Share Growth Rate was -87.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of XORTX Therapeutics was 38.10% per year. The lowest was -134.70% per year. And the median was -11.40% per year.

Competitive Comparison of XORTX Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, XORTX Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's 3-Year EBITDA Growth Rate falls into.

XORTX Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

XORTX Therapeutics (NAS:XRTX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

XORTX Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.